recal classifi class fda
expect impact novemb letter
materi view reiter outperform
today fda announc class recal expect follow mdt
novemb patient letter relat voluntari recal replac select
minim insulin pump model notif agenc compani replac
pump pumper ww experienc loos damag miss
retain ring manag expect cost replac insulin pump
materi current estim updat sinc announc
recal believ project adequ contempl potenti impact
recal reiter outperform rate target price
natur novemb letter patient sent letter patient
novemb warn risk loosen pump insulin reservoir
due part potenti retain ring break prevent proper lock
reservoir loos reservoir may lead either rapid hinder infus insulin
over- under-infus insulin potenti caus either hypoglycemia
hyperglycemia peopl diabet pwd begun product improv
made pump octob better withstand damag retain ring pump
due accident drop bump hard surfac
continu expect mdt diabet sale declin due
continu share loss mdt diabet busi remain challeng compris
primarili pump relat sensor consum despit on-going share
loss competit challeng continu expect busi stabil
come quarter begin regain momentum driven part
upcom minim launch pleas see recent preview
what new initi voluntari recal minim
pump model us receiv
complaint relat devic malfunct awar injuri death given
potenti sever fda class announc expect
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
mariu zoican univers toronto rotman school manag februari
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
medtron plc global manufactur provid medic devic
equip area cardiac rhythm manag vascular
intervent structur valvular diseas spinal disord
neuromodul surgic equip diabet
one-year valuat scenario base
ev/ebitda ntm ebitda estim bil
one year forward scenario base emerg segment
deliv growth high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ntm ebitda estim bil
one year forward grey scenario base emerg segment
deliv growth high-growth segment grow
growth grow
 close
mariu zoican univers toronto rotman school manag
context fda class recal classif
fda classif mdt pump recal class indic agenc assess
sever risk patient risk injuri death assess compani initi
action novemb surpris agenc would classifi recal class
given natur devic potenti advers event relat over- under-suppli
insulin peopl diabet although abl confirm management
understand time remain unclear whether malfunct pump fact
play signific role report death patient associ issu
valuat target price base ebitda multipl ntm ebitda
estim bil one year forward risk product delay failur progress long-term
goal growth margin potenti new
mariu zoican univers toronto rotman school manag februari
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
